Q32 Bio Inc.

QTTBSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1661998

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	$3.2M	$34.0M	$2.7M
Research and Development Expense	$48.1M	$31.7M	$98.4M	$93.1M	$100.4M
Operating Expenses	$66.1M	$41.6M	$136.5M	$129.9M	$133.0M
Operating Income (Loss)	-$66.1M	-$48.3M	-$133.3M	-$95.9M	-$130.3M
Nonoperating Income (Expense)	$20.0M	-$5.2M	—	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	—	$1.2M	-$95.8M	—
Income Tax Expense (Benefit)	$21.0K	$318.0K	$715.0K

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$92.3M	$47.1M	$228.5M	$211.7M	$263.7M
Assets, Current	$81.9M	$28.7M	$181.0M	$191.9M	$219.6M
Cash and Cash Equivalents, at Carrying Value	$78.0M	$25.6M	$34.0M	$108.4M	$217.4M
Liabilities	$86.7M	$118.5M	$50.5M	$42.1M	$67.7M
Liabilities, Current	$16.5M	$14.1M	$22.6M	$17.2M	$22.7M
Accounts Payable, Current	$3.0M	$3.5M	$1.1M	$2.4M	$4.7M
Stockholders' Equity Attributable to Parent	-$182.9M	-$130.7M	$169.7M	$196.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$67.7M	-$18.7M	-$113.7M	-$109.8M	-$94.3M
Net Cash Provided by (Used in) Investing Activities	$19.9M	-$5.0K	$36.7M	-$50.8M	$204.9M
Net Cash Provided by (Used in) Financing Activities	$95.1M	$406.0K	$596.0K	$52.2M	$53.1M
Payments to Acquire Property, Plant, and Equipment	$75.0K	$5.0K	$1.3M	$2.4M	$3.7M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)